Kymera Therapeutics, Inc. announced on May 19, 2025, the presentation of additional preclinical data for KT-621, its potent, selective, oral STAT6 degrader, at the American Thoracic Society (ATS) International Conference. The new asthma efficacy mouse model data demonstrated both prevention of disease progression and reversal of established disease.
KT-621 showed comparable or superior activity to dupilumab in blocking Th2 inflammation in the HDM-induced chronic mouse model with a therapeutic treatment regimen. New histology data from this model also showed amelioration of lung remodeling, including goblet cell metaplasia and MUC5AC mRNA expression, after low daily oral doses of KT-621, which was superior to dupilumab.
The company has completed the Phase 1 healthy volunteer trial for KT-621, with data expected to be reported in June 2025. The KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis patients is ongoing, with data expected in the fourth quarter of 2025. Two parallel Phase 2b trials in AD and asthma are planned to start in the fourth quarter of 2025 and the first quarter of 2026, respectively.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.